Clinical Trials: Mental Health
MEM-MD 91 An Open-label study of the safety and tolerability of Memantine in Pediatric patients(6-12 y.o.) with Autism, AspergersDisorder or Pervasive Deveopmental Disorder Not otherwise Specified. (IRB# 338277-11)
|(Children's health, Mental health)|
- Principal Investor
Bruce Waslick, MD
The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).
- More Information
Must be between the ages of 6-12 and meet the criteria for diagnosis of autism, Asperger’s Disorder or Pervasive Developmental Disorder not otherwise specified.
- Study Site Location
3300 Main Street, Springfield, MA